Literature DB >> 6772673

Monoclonal immunoglobulin M lambda coagulation inhibitor with phospholipid specificity. Mechanism of a lupus anticoagulant.

P Thiagarajan, S S Shapiro, L De Marco.   

Abstract

Prolongation of all phospholipid-dependent coagulation tests was found in a patient with macroglobulinemia, despite absence of bleeding manifestations. The purified monoclonal IgM lambda protein and its Fabmu tryptic fragment induced similar changes in normal plasma. Patient IgM and Fabmu completely inhibited Ca++-dependent binding of radiolabeled prothrombin and Factor X to mixed phospholipid micelles. The patient's IgM lambda paraprotein reacted with phosphatidylserine and, to a lesser extent, with phosphatidylinositol and phosphatidic acid, but not with phosphatidylcholine or phosphatidylethanolamine. Prior incubation of phospholipid with patient Fabmu blocked the positive reactions. Substitution of washed platelets for phospholipid led to normalization of patient coagulation tests and corrected all abnormalities produced in normal plasma by patient IgM. Furthermore, binding of 125I-Factor Xa to thrombin-treated platelets was entirely normal in the presence of patient IgM. These studies support the concept that platelets, rather than phospholipid micelles, are the primary locus of prothrombin and Factor X activation in normal hemostasis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6772673      PMCID: PMC371666          DOI: 10.1172/JCI109869

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  44 in total

Review 1.  Acquired inhibitors of blood coagulation.

Authors:  D I Feinstein; S I Rapaport
Journal:  Prog Hemost Thromb       Date:  1972

Review 2.  Immunoglobulin-producing tumors and myeloma proteins of mice.

Authors:  M Potter
Journal:  Physiol Rev       Date:  1972-07       Impact factor: 37.312

3.  Studies on human platelet granules and membranes.

Authors:  A J Marcus; D Zucker-Franklin; L B Safier; H L Ullman
Journal:  J Clin Invest       Date:  1966-01       Impact factor: 14.808

4.  The action of thrombin on blood clotting factor V: conversion of factor V to a prothrombin-binding protein.

Authors:  C T Esmon; W G Owen; D L Duiguid; C M Jackson
Journal:  Biochim Biophys Acta       Date:  1973-05-17

5.  The asymetric arrangement of phospholipids in the human erythrocyte membrane.

Authors:  S E Gordesky; G V Marinetti
Journal:  Biochem Biophys Res Commun       Date:  1973-02-20       Impact factor: 3.575

6.  [Anticardiolipin activity linked to a Waldenstrom macroglobulin-cryoprecipitant IgG complex].

Authors:  R Gisler; J Pillot
Journal:  Immunochemistry       Date:  1968-11

Review 7.  The role of lipids in blood coagulation.

Authors:  A J Marcus
Journal:  Adv Lipid Res       Date:  1966

8.  Immunoglobulin M: pentameric Fcmu fragments released by trypsin at higher temperatures.

Authors:  A G Plaut; T B Tomasi
Journal:  Proc Natl Acad Sci U S A       Date:  1970-02       Impact factor: 11.205

9.  The purification of human prothrombin.

Authors:  S S Shapiro; D F Waugh
Journal:  Thromb Diath Haemorrh       Date:  1966-12-01

10.  Human prothrombin metabolism in normal man and in hypocoagulable subjects.

Authors:  S S Shapiro; J Martinez
Journal:  J Clin Invest       Date:  1969-07       Impact factor: 14.808

View more
  57 in total

Review 1.  Neuroimaging techniques in the diagnostic work-up of patients with the antiphospholipid syndrome.

Authors:  M Rovaris; C Pedroso; M Filippi
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

Review 2.  Influence of the lupus anticoagulant on clotting tests.

Authors:  J Vermylen; J Arnout
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Lupus anticoagulant activities of murine monoclonal antibodies to liposomal phosphatidylinositol phosphate.

Authors:  B M Alving; B Banerji; W E Fogler; C R Alving
Journal:  Clin Exp Immunol       Date:  1987-08       Impact factor: 4.330

4.  Lupus anticoagulant: clinical significance in anticardiolipin positive patients with systemic lupus erythematosus.

Authors:  N J McHugh; D A Moye; I E James; M Sampson; P J Maddison
Journal:  Ann Rheum Dis       Date:  1991-08       Impact factor: 19.103

5.  Methods for detecting lupus anticoagulants and their relation to thrombosis and miscarriage in patients with systemic lupus erythematosus.

Authors:  D Ferro; M Saliola; C Quintarelli; G Valesini; S Basili; A M Grandilli; M S Bonavita; F Violi
Journal:  J Clin Pathol       Date:  1992-04       Impact factor: 3.411

Review 6.  Anti-beta 2-glycoprotein I antibodies and thrombosis.

Authors:  J P Viard; Z Amoura; J F Bach
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

Review 7.  Detection of lupus anticoagulants.

Authors:  M H Horellou; M M Samama
Journal:  Clin Rev Allergy Immunol       Date:  1995       Impact factor: 8.667

8.  Fetal loss treatment in patients with antiphospholipid antibodies.

Authors:  J Ordi; J Barquinero; M Vilardell; R Jordana; C Tolosa; A Selva; E Genover
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

9.  Calorie restriction prevents the occlusive coronary vascular disease of autoimmune (NZW x BXSB)F1 mice.

Authors:  H Mizutani; R W Engelman; K Kinjoh; Y Kurata; S Ikehara; Y Matsuzawa; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-10       Impact factor: 11.205

10.  The lupus anticoagulant, pulmonary thromboembolism, and fatal pulmonary hypertension.

Authors:  N E Anderson; M R Ali
Journal:  Ann Rheum Dis       Date:  1984-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.